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Aims The value of clinical definitions of the metabolic syndrome has been questioned, 
with confusion surrounding their intended use and purpose. Our aim was to construct a 
mission statement that outlines the value of the metabolic syndrome in clinical and public 
health settings. 
Methods Case studies have been used to demonstrate three key points.  
Results We argue here for recognition of obesity as being a crucial element within the 
metabolic syndrome but perhaps even more important before its development. We also 
contend that the concept does indeed have a role as a risk prediction tool, and that it could 
provide a useful metric for the scale and progress of the looming global epidemic of 
diabetes and cardiovascular disease. 
Conclusions Through appreciation of its purpose, and recognition of both its limitations 
and those attributes that make it unique and valuable, we believe we have demonstrated 
here that the metabolic syndrome deserves its place in the global toolbox of diabetes and 
CVD prevention. 
 
The metabolic syndrome has suffered from a lack of clarity regarding its intended use and 
raison d’etre. This has led some to question its value in clinical practice and as a public 
health tool.[1, 2] The major stated rationale for the main definitions of the syndrome is to 
identify patients at high risk of clinical atherosclerotic disease and type 2 diabetes 
mellitus in order to institute preventive measures to reduce these risks.[3, 4] In addition, 
the International Diabetes Federation (IDF) definition of the metabolic syndrome, in 
particular, was designed to be useful globally in primary as well as specialist care, and in 
resource poor settings. 
Recent reports indicate that even though the metabolic syndrome does independently 
predict both cardiovascular disease and type 2 diabetes, it is not necessarily the most 
effective tool for this purpose.[5-8] Doubt about the utility of the syndrome in clinical 
practice means that it is timely to consider whether the current high level of interest in the 
metabolic syndrome is misplaced, or if it does indeed deserve an important place in the 
global fight against diabetes and cardiovascular disease (CVD). 
We propose here that the attributes of the metabolic syndrome that make it a potentially 
valuable global public health tool are the emphasis it places on central obesity (although 
we contend that this emphasis requires a subtle shift), its ability to identify high risk 
individuals at a young age and the possibilities provided by its dichotomous structure.  
Obesity: important in the metabolic syndrome, more important before 
the syndrome develops 
We will begin our explanation of this view by focusing on obesity and its role in the 
syndrome.  
A thirty year old male has a waist circumference of 130cm (and a BMI of 35kg/m2) and 
is therefore markedly obese, but doesn’t (yet) have the hypertension, dyslipidaemia or 
elevated blood glucose characteristic of the metabolic syndrome.  
Q. What is his risk of diabetes using available calculators?  
A. Low (using the Finnish diabetes risk score,[9] even if he also does no exercise and 
never eats fruit or vegetables (but is without a family history of diabetes), his 10 year 
diabetes risk is described as only “slightly elevated”. Using the San Antonio Heart study 
diabetes prediction model,[10] with a fasting plasma glucose of 5.0 mmol/L and normal 
blood pressure and HDL cholesterol readings, he has a 7.5 year risk of developing 
diabetes of <5%) 
 
Q. What is his risk of coronary heart disease using available calculators?  
A. Negligible. (Even with a substantial risk factor burden, 10 year CHD risk estimates in 
young men have been shown to remain low.[11] In this case, it is only 1%.[12]) 
 
Q. Those calculators all estimate only short term risk (10 years or less). Is he at high 
lifetime risk of these conditions?  
A. Absolutely (Obesity is a major risk factor for diabetes, and its strong relationship with 
CHD morbidity and mortality becomes apparent with longer-term followup.[13-15] 
 Q.  Does his low short term risk and the fact that he does not meet the criteria for the 
metabolic syndrome mean that he does not need to try to reduce his risk?  
A. Absolutely not. His extreme obesity at such a young age means a very high lifetime 
risk of developing the other components of the MetS, and subsequent CHD and diabetes. 
Indeed, his young age means a longer time at risk and the potential for greater expense, 
disability and suffering. His childhood and early adulthood were actually the best time to 
intervene when behaviour is more modifiable. But better late than never. 
 
This example serves to highlight the importance of recognizing that obesity is a risk 
factor in its own right, and one that can often be present before the appearance of the 
metabolic syndrome proper.  
The emphasis on obesity in a definition of the metabolic syndrome is perhaps less 
important than acknowledging that obesity is the most important modifiable risk factor 
before the metabolic syndrome even develops. Our recent research supports this view, 
demonstrating that central obesity precedes deterioration in each of the components that 
constitute the metabolic syndrome.[16]  As a metaphor, obesity can be thought of as the 
sea retreating before the tsunami of metabolic syndrome, then diabetes and CVD roll in. 
The important role of obesity in the metabolic syndrome is as a warning sign for future 
disease, not as a correlate for disease that is already present. The Japanese government 
has clearly understood this, recently announcing laws requiring all companies and local 
governments to measure waistlines of their 40-74 year old employees annually (44% of 
the entire Japanese population).[17] We suggest that definitions of the metabolic 
syndrome need to acknowledge this important point, recognising the importance of 
obesity in the metabolic syndrome, but placing greater emphasis on the role of obesity 
before the metabolic syndrome has even developed. Having said this, it is also important 
to recognize that a sub-population of obese patients may exist who will remain 
metabolically healthy despite their excess body fat, and who may be protected against 
obesity-related metabolic complications.[18] 
The metabolic syndrome: a CVD and type 2 diabetes risk prediction 
tool after all 
Q. If this young man from our earlier example also had hypertension (systolic BP 
150mmHg) and total cholesterol of 6.5mmol/L and met the criteria for the metabolic 
syndrome, which of the metabolic syndrome or a CVD risk algorithm would identify him 
as someone at high future CVD risk? 
A. His 10 year calculated risk of CHD[12] is still only 1%, and even if he was also a 
smoker, this would still be less than 10%. By meeting the criteria for the metabolic 
syndrome, however, this individual is clearly identified as someone at high lifetime risk 
of CVD and diabetes. Indeed, Sundstrom et al. recently demonstrated the long term value 
of the metabolic syndrome in predicting total and cardiovascular mortality independently 
of age, smoking, diabetes, hypertension and cholesterol.[19] 
 
Because of the influence of age in risk prediction models and the fact that they only 
predict short term risk, the importance of risk factors such as obesity in younger people is 
often ignored. The opportunity for preventive intervention is ripe well before most people 
will qualify as “high risk” on risk prediction models, which are often difficult to use and 
interpret.[20] It is the high lifetime risk which is more important than the comparatively 
low 10 year risk. The absence of an age criterion in definitions of the metabolic 
syndrome, while reducing its overall predictive ability, means that it goes some way to 
recognizing that those with signs of serious metabolic deterioration at a young age are at 
very high lifetime risk of diabetes and CVD.   
It has now become clear that the metabolic syndrome is not the best predictor of global 
cardiovascular or diabetes risk and misses those persons whose risk is not mediated by 
metabolic syndrome parameters.[21, 22] For these reasons, and because clinical 
definitions do not acknowledge increasing numbers or severity of components as an even 
greater risk, the arguments we have made for the value of the syndrome need to be kept 
in context. In isolation, the metabolic syndrome is an imperfect tool for the identification 
of those at high risk of future CHD or diabetes. In combination with the knowledge that 
other risk factors for these conditions are also important, and used in combination with 
good clinical judgment and other appropriate tools, the metabolic syndrome does, 
however, have an important clinical function. It highlights the role obesity often plays in 
metabolic deterioration. It can help patients understand the inter-related nature of the 
syndrome’s components and finally, when present it suggests the need for intensive 
intervention to prevent diabetes and CVD. Just as measurement of obesity in itself is not 
the optimal tool for CHD or diabetes risk prediction, neither is the metabolic syndrome 
(or any other risk prediction device). Each, however, has characteristics that make them 
important clinical and public health tools. 
The metabolic syndrome: more than just risk prediction 
We conclude by suggesting that the debate surrounding the metabolic syndrome’s risk 
prediction qualities has meant that other important features of the syndrome have been 
ignored. We demonstrate the public health value of the metabolic syndrome by answering 
some of the key questions relating to its mission statement, and by suggesting an 
alternative perspective on the utility of the concept.  
Q. Was the metabolic syndrome designed to be the optimal short to medium term risk 
prediction device for CVD or diabetes?  
A. No, as we discussed earlier, it is obvious that other risk factors specific to these two 
conditions (as well as age and sex) would be required to determine risk optimally. It is 
important to acknowledge, however, that all available risk prediction devices have flaws 
and none can be used as the sole basis for clinical decisions. The metabolic syndrome as 
currently defined was never intended as an absolute risk indicator – rather as an early 
warning system. 
Q. Does a diagnosis of the metabolic syndrome actually identify a population at high risk 
of CVD and diabetes?  
A. Yes, as has been repeatedly shown.[23]  
Q. Other than predicting absolute CVD and type 2 diabetes risk (for which it, as well as 
all other available risk prediction devices, are imperfect), are there other features of the 
metabolic syndrome that provide further value? 
A. We contend that in addition to the important clinical attributes identified earlier, an 
under-recognised use for the metabolic syndrome is a global metric that identifies a 
looming epidemic of CVD and diabetes.  
Q. How will the coming global diabetes epidemic (most of which will occur in 
developing countries)[24] and the resultant CVD be prevented?  
A. Identification of those at high short term risk of diabetes and CVD and intensive 
medical intervention can only be a small part of the solution, particularly in developing 
countries. Population level lifestyle modification requires a big picture approach that 
addresses the structural and environmental causes of an obesogenic environment and is 
reliant on support of all levels of government, the public as well as health care providers.  
We explain below how the metabolic syndrome helps each of these stakeholders do just 
this. 
 
Two pieces of information that will help any country appreciate the urgency of 
implementing measures to prevent diabetes and CVD, and chart their progress toward 
that aim, are the prevalence of obesity (the warning of a tsunami to come), and the 
prevalence of the metabolic syndrome (how much of the tsunami has already arrived). As 
a metric, the metabolic syndrome allows comparisons of the scale of the tsunami both 
between countries (at least those of similar ethnicity) and across time, with all of its 
elements being modifiable through lifestyle alteration. Although often under-appreciated, 
quantifying the magnitude of a problem and how it changes over time is crucial for public 
and political awareness, and to inform funding decisions and preventive measures. Over 
the previous few decades, tracking the trends in smoking, hypertension and cholesterol 
might have been a good way of predicting future changes in CVD. As the importance of 
CVD risk factors shifts to metabolic abnormalities and obesity, the metabolic syndrome 
may have a valuable role to play in predicting future disease burden, and one that cannot 
be filled by other risk prediction models.  
 
In conclusion, the metabolic syndrome was not designed to be a tool that optimally 
predicts absolute risk of future CVD and type 2 diabetes. It is clear, however, that those 
with the metabolic syndrome do constitute a population at high risk of both. We have 
demonstrated here that a diagnosis of the metabolic syndrome can add valuable 
information regarding future risk, particularly among the young, and should therefore be 
seen as an additional device in the toolbox of diabetes and CVD prevention. As a metric 
allowing comparison of the scale of an impending epidemic between countries or 
population groups and across time, the metabolic syndrome differentiates itself as a 
unique tool for the global prevention of diabetes and CVD. The emphasis on central 
obesity in the metabolic syndrome should be as a pre-cursor to the development of the 
syndrome itself, not as a correlate for disease that is already present, with lifestyle 
intervention being important as soon as obesity is present, particularly in the young.  
To build on the considerable awareness of the metabolic syndrome and achieve the 
potential we have identified, a single global definition (with appropriate consideration of 
ethnic differences) is imperative. By ensuring that obesity is recognised as an important 
warning sign before the metabolic syndrome even appears, and recognising and 
appreciating those attributes that make the concept unique and valuable, the metabolic 
syndrome should be a much needed tool in the campaign to prevent the devastating 
consequences of a global diabetes and CVD epidemic. 
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